logo

Breaking News

Share

An FDA panel has recommended that regulatory decision on Incyte's (INCY) Retifanlimab injection should be delayed until more data are available. Retifanlimab is proposed as a potential treatment of adult patients with locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) who have...

Mortgage rates, or interest rates on home loans, rose above 3% in ten weeks, according to mortgage provider Freddie Mac (FMCC.OB). Releasing the results of its primary mortgage market survey, Freddie Mac said that the 30-year fixed-rate mortgage or FRM averaged 3.02 percent for the week ending June...

Aurubis AG (AIAGY.PK, AIAGF.PK) said that it started the construction of a 10-megawatt (MW) solar power plant near its production site in Bulgaria. It is part of Aurubis' strategic goal of carbon-neutral production by 2050 at the latest. The Aurubis-1 PV plant will optimize the smelter's external...

Carnival Corporation & plc (CUK, CCL, CCL.L) reported that its second-quarter net loss narrowed to $2.07 billion from $4.37 billion last year. Adjusted net loss was $2.04 billion compared to a loss of $2.38 billion in the previous year. Booking volumes for all future cruises during the second...

Wendy's Co. (WEN), the owners of Kusto Group, and Global Investors Limited (Wissol Group) announced Thursday three strategic development agreements to expand Wendy's brand presence in the Central Asia Region over the next nine years. The quick-service restaurant chain is strategically collaborating...

Gilead Sciences Inc. (GILD) said that treatment with hepcludex or bulevirtide was shown to achieve significant response in chronic hepatitis delta virus after 24 weeks. Interim phase 2b and phase 3 data are consistent with previous results and reinforce the clinical profile of hepcludex in adults with...

Bristol Myers Squibb exercised its option under the global neuroscience research and development collaboration to enter into an exclusive U.S. license for PRX005. Bristol Myers will pay Prothena $80 million, Prothena Corporation plc (PRTA) said in a statement. PRX005 is designed to be a best-in-class...

Amazon (AMZN) and Asmodee Group SAS, a board game publisher and distributor, jointly filed a lawsuit against two defendants for counterfeiting the card game sets, Dixit: Daydreams Expansion and Dixit: Revelations Expansion, the e-commerce giant said in a statement on Thursday. The defendants, based...

Immunology company Corbus Pharmaceuticals Holdings Inc. (CRBP) announced Thursday topline results from the Phase 3 DETERMINE study of lenabasum in adults with the rare, heterogeneous, autoimmune disease dermatomyositis. The study did not meet its primary endpoint of Total Improvement Score (TIS) at...

AbbVie (ABBV) said that it exercised its exclusive right to buy TeneoOne, an affiliate of Teneobio Inc., and lead asset TNB-383B for the potential treatment of relapsed or refractory multiple myeloma. The decision was based on an interim analysis of an ongoing phase 1 study. Interim results from...

Public Service Enterprise Group, Inc. or PSEG (PEG) announced Thursday the acceleration of its net-zero ambitions by launching a three-pronged 2030 climate vision that extends across its business. The PSEG climate vision marks one of the first and most aggressive net-zero 2030 visions set by a large...

STMicroelectronics (STM) said that it has collaborated with Arrival (ARVL), the global technology company creating electric vehicles or EVs using its unique technologies, to provide semiconductor technologies and products for Arrival's vehicles including automotive microcontrollers and power and battery-management...

Fulcrum Therapeutics Inc. (FULC) said Thursday that its phase 2b trial for people with facioscapulohumeral muscular dystrophy or FSHD did not meet its primary endpoint. Changes in DUX4-driven gene expression, which were included in the trial as an experimental biomarker endpoint, could not be demonstrated,...

Medical technology firm Boston Scientific Corp. (BSX) announced Thursday it exercised its option to acquire the remaining 73 percent stake in Farapulse, Inc. for an upfront payment of approximately $295 million, up to $92 million upon achievement of certain clinical and regulatory milestones as well...

RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (ALNY) announced Thursday that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for vutrisiran, an investigational RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated...

Follow RTT